Latest News

Prostate-specific antigen (PSA) kinetics predicts survival in castration-resistant prostate cancer (CRPC); however, the influence of prior treatment on this relationship is unclear. Patients with CRPC were stratified according to time to PSA nadir and time to CRPC progression to investigate their prognostic significance on prostate cancer-specific survival (PCSS) and whether PSA kinetics may serve as […]

Prostate-specific membrane antigen (PSMA) is overexpressed in metastatic castration-resistant prostate cancer (mCRPC) and represents a target for imaging and therapy. We undertook a prospective trial of 177Lu-PSMA-617 radioligand therapy in men with high PSMA expression who progressed after standard therapies. To determine outcomes for men screened for the trial but not treated because of low […]

Lineage plasticity has emerged as an important mechanism of treatment resistance in prostate cancer (PC). Treatment refractory PCs are increasingly associated with loss of luminal prostate markers, and in many cases induction of developmental programs, stem cell-like phenotypes, and neuroendocrine/neuronal features. Clinically, lineage plasticity may manifest as low prostate specific antigen (PSA) progression, resistance to […]

An increasingly recognized resistance mechanism to androgen receptor (AR)-directed therapy in prostate cancer involves epithelial plasticity, in which tumor cells demonstrate low to absent AR expression and often have neuroendocrine features. The etiology and molecular basis for this ‘alternative’ treatment-resistant cell state remain incompletely understood. Here, by analyzing whole-exome sequencing data of metastatic biopsies from […]

177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer Condition: Metastatic Castration Resistant Prostate Cancer (mCRPC) Intervention: Drug: Olaparib Combination Product: 177Lu-PSMA Purpose: This phase 1 dose-escalation and dose-expansion study is designed to evaluate the safety and tolerability of olaparib in combination with 177Lutetium-Prostate Specific Membrane Antigen (177 Lu-PSMA) in patients with […]

A Phase II Study of Olaparib and Durvalumab in Men With Castration Sensitive Biochemically Recurrent Non-Metastatic Prostate Cancer Harboring Mutations in DNA Damage Repair Condition: Prostate Cancer Intervention: Drug: Olaparib Drug: Durvalumab Purpose: The purpose of this study is to determine if the combination of olaparib and durvalumab are better than the standard of care […]

Open-Label, Pilot Study of Olaparib as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer Condition: ATM Biallelic Inactivation, ATM Gene Mutation, ATM Monoallelic Inactivation, BRCA1 Biallelic Inactivation, BRCA1 Gene Mutation, BRCA2 Biallelic Inactivation, BRCA2 Gene Mutation, FANCA Biallelic Inactivation, Homologous Recombination Deficiency, PALB2 Biallelic Inactivation, PALB2 Gene Mutation, Prostate Adenocarcinoma Without Evidence […]

BrUOG 337: Olaparib Prior to Radical Prostatectomy For Patients With Locally Advanced Prostate Cancer and Defects in DNA Repair Genes Condition: Prostate Cancer, Adenocarcinoma of the Prostate Intervention: Drug: Olaparib Pill Procedure: Prostatectomy Purpose: This study will evaluate approximately 3 months of treatment with the drug olaparib in patients with prostate cancer. A capsule formulation […]

Phase II Trial Evaluating Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response. Condition: Prostate Cancer Metastatic Intervention: Drug: Olaparib Purpose: A number of important systemic therapies have been developed to treat mCRPC and have received regulatory approval and now comprise the current therapeutic landscape. Durable and complete response following […]

A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE) Condition: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma Metastatic in the Bone, PSA Level Greater Than or Equal to Two, PSA Progression Intervention: Other: Laboratory Biomarker Analysis Drug: Olaparib Radiation: Radium […]